These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 23170122)

  • 1. Challenging delivery of VLHL NS plasminogen activator inhibitor-1 by osmotic pumps in diabetic mouse: A case report.
    Jankun J
    Exp Ther Med; 2012 Oct; 4(4):661-664. PubMed ID: 23170122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis.
    Jankun J; Aleem AM; Selman SH; Skrzypczak-Jankun E; Lysiak-Szydlowska W; Grafos N; Fryer HJ; Greenfield RS
    Int J Mol Med; 2007 Nov; 20(5):683-7. PubMed ID: 17912461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Very long half-life plasminogen activator inhibitor type 1 reduces bleeding in a mouse model.
    Jankun J; Selman SH; Keck RW; Łysiak-Szydłowska W; Skrzypczak-Jankun E
    BJU Int; 2010 May; 105(10):1469-76. PubMed ID: 19912209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic or topical application of plasminogen activator inhibitor with extended half-life (VLHL PAI-1) reduces bleeding time and total blood loss.
    Jankun J; Keck R; Selman SH; Skrzypczak-Jankun E
    Int J Mol Med; 2010 Oct; 26(4):501-4. PubMed ID: 20818488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison between the clot-protecting activity of a mutant plasminogen activator inhibitor-1 with a very long half-life and 6-aminocaproic acid.
    Kindell DG; Keck RW; Jankun J
    Exp Ther Med; 2015 Jun; 9(6):2339-2343. PubMed ID: 26136983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. VLHL plasminogen activator inhibitor spontaneously reactivates from the latent to active form.
    Jankun J; Aleem AM; Selman SH; Basrur V; Skrzypczak-Jankun E
    Int J Mol Med; 2009 Jan; 23(1):57-63. PubMed ID: 19082507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accelerated thrombus lysis in the blood of plasminogen activator inhibitor deficient mice is inhibited by PAI-1 with a very long half-life.
    Jankun J; Aleem AM; Struniawski R; Lysiak-Szydłowska W; Selman SH; Skrzypczak-Jankun E
    Pharmacol Rep; 2009; 61(4):673-80. PubMed ID: 19815949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasminogen activator inhibitor-1 and diabetic nephropathy.
    Lee HB; Ha H
    Nephrology (Carlton); 2005 Oct; 10 Suppl():S11-3. PubMed ID: 16174279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasminogen activator inhibitor with very long half-life (VLHL PAI-1) can reduce bleeding in PAI-1-deficient patients.
    Jankun J; Skrzypczak-Jankun E
    Cardiovasc Hematol Disord Drug Targets; 2013 Aug; 13(2):144-50. PubMed ID: 23988002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasminogen activator inhibitor-1 in kidney pathology (Review).
    Małgorzewicz S; Skrzypczak-Jankun E; Jankun J
    Int J Mol Med; 2013 Mar; 31(3):503-10. PubMed ID: 23314920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of long-acting VLHL PAI-1 during sutureless partial nephrectomy in mice reduces bleeding.
    Shahrour K; Keck R; Jankun J
    Biomed Res Int; 2015; 2015():392862. PubMed ID: 25883959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasminogen activator inhibitor-1 deficiency retards diabetic nephropathy.
    Nicholas SB; Aguiniga E; Ren Y; Kim J; Wong J; Govindarajan N; Noda M; Wang W; Kawano Y; Collins A; Hsueh WA
    Kidney Int; 2005 Apr; 67(4):1297-307. PubMed ID: 15780082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rosiglitazone prevents advanced glycation end products-induced renal toxicity likely through suppression of plasminogen activator inhibitor-1.
    Yu X; Li C; Li X; Cai L
    Toxicol Sci; 2007 Apr; 96(2):346-56. PubMed ID: 17264099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasminogen activator inhibitor-1 deficiency has renal benefits but some adverse systemic consequences in diabetic mice.
    Collins SJ; Alexander SL; Lopez-Guisa JM; Cai X; Maruvada R; Chua SC; Zhang G; Okamura DM; Matsuo S; Eddy AA
    Nephron Exp Nephrol; 2006; 104(1):e23-34. PubMed ID: 16735799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasminogen activator inhibitor type 1 is a potential target in renal fibrogenesis.
    Rerolle JP; Hertig A; Nguyen G; Sraer JD; Rondeau EP
    Kidney Int; 2000 Nov; 58(5):1841-50. PubMed ID: 11044203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reactive oxygen species mediate high glucose-induced plasminogen activator inhibitor-1 up-regulation in mesangial cells and in diabetic kidney.
    Lee EA; Seo JY; Jiang Z; Yu MR; Kwon MK; Ha H; Lee HB
    Kidney Int; 2005 May; 67(5):1762-71. PubMed ID: 15840023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Remarkable extension of PAI-1 half-life surprisingly brings no changes to its structure.
    Jankun J; Yang J; Zheng H; Han FQ; Al-Senaidy A; Skrzypczak-Jankun E
    Int J Mol Med; 2012 Jan; 29(1):61-4. PubMed ID: 21947232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal synthesis of urokinase type-plasminogen activator, its receptor, and plasminogen activator inhibitor-1 in diabetic nephropathy in rats: modulation by angiotensin-converting-enzyme inhibitor.
    Kenichi M; Masanobu M; Takehiko K; Shoko T; Akira F; Katsushige A; Takashi H; Yoshiyuki O; Shigeru K
    J Lab Clin Med; 2004 Aug; 144(2):69-77. PubMed ID: 15322501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Plasminogen Activator Inhibitor-1 Inhibitors Prevent Diabetic Kidney Injury in a Mouse Model.
    Jeong BY; Uddin MJ; Park JH; Lee JH; Lee HB; Miyata T; Ha H
    PLoS One; 2016; 11(6):e0157012. PubMed ID: 27258009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sulodexide ameliorates early but not late kidney disease in models of radiation nephropathy and diabetic nephropathy.
    Rossini M; Naito T; Yang H; Freeman M; Donnert E; Ma LJ; Dunn SR; Sharma K; Fogo AB
    Nephrol Dial Transplant; 2010 Jun; 25(6):1803-10. PubMed ID: 20061322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.